Researchers suggest targeting mTOR activity in aggressive cancers by blocking cholesterol sensing may represent a promising ...
While many American adults are trying to reduce cholesterol levels, certain cancerous tumors have a relentless appetite for ...
Paligenosis defines a tightly controlled program through which terminally differentiated cells re‑enter the cell cycle and ...
Findings of a new study introduce new drug targets to selectively inhibit a key event in tumor cell progression. The study provides further insight into the control of mTORC1 activation, and ...
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results